

FIG. 1b




FIG. 1d




FIG. 1a






FIG. 1c

**BOLUS INJECTIONS OF 0.1  $\mu\text{mol/kg}$  S-NO-HSA +  
GSH ( $\mu\text{mol/kg}$ ) – *in vivo***



**FIG. 1e**

+



**FIG. 1f**

+

**Potentiation of the NO-release of S-NO-HSA (30  $\mu\text{mol/L}$ ) by GSH**  
(in vitro, n=6, \* $P<0.05$  vs S-NO-HSA; # $P<0.05$  vs GSH 25  $\mu\text{mol/L}$ )




FIG. 2a

**Potential of the NO-release of S-NO-HSA by GSH**  
(In vitro; phsiol. NaCl, pH=6.5)




FIG. 2b

Dose-dependent potentiation of the inhibition of the collagen-induced platelet aggregation by S-NO-HSA (2 - 4  $\mu\text{mol/L}$ ) with reduced glutathione




FIG. 3a

+

Effect of N-acetyl cysteine (1 mmol/L), ascorbic acid (Vit.C; 200  $\mu$ mol/L), reduced glutathione, homocysteine, taurine and cysteine (1 mmol/L in each case) on the inhibition of the collagen-induced platelet aggregation by S-NO-HSA (2 - 4  $\mu$ mol/L)




FIG. 3b

+




FIG. 4c

FIG. 4b

FIG. 4a